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In spite of all advances in the understanding of chronic di-
abetic complications, diabetic retinopathy remains a signiﬁ-
cant clinical problem. The pathogenetic mechanisms leading
to the development of diabetic retinopathy is indeed com-
plex. Multiple interactive mechanisms may come into play
leading to cellular damage and adaptive changes leading to
thedevelopmentofthisdevastatingcomplicationofdiabetes.
In this focused issue of the journal we have assembled
several invited reviews, from well-recognized experts in their
ﬁelds, as well as original research articles. These reviews pro-
vide state-of-the-art knowledge dealing with several mech-
anisms, all of which contribute to the development of di-
abetic retinopathy. The reviews include discussion on sev-
eralpathogeneticmechanismssuchaspolyolpathway,oxida-
tive stress, cellular signaling, inﬂammatory changes, and ex-
citatory amino acids as well as pharmacotherapy in diabetic
retinopathy. In addition, several excellent original research
articles demonstrate novel pathophysologic aspects of this
disease process which ranges from population-based studies
to mechanistic studies.
It is becoming more and more evident that early di-
abetic retinopathy is associated with increased production
of several inﬂammatory mediators. Several pharmacological
approaches by inhibiting production of inﬂammatory me-
diators are eﬀective in preventing early lesions of diabetic
retinopathy. Although this concept is relatively new, it has
enormous potential as a drug target. Dr. T. S. Kern has dis-
cussed the inﬂammatory process in the pathogenesis of early
stages of diabetic retinopathy.
Dr. M. Lorenzi has reviewed polyol pathway activation as
a mechanism for diabetic retinopathy. Interest in this path-
way stems from the fact that it remains one of the attrac-
tive mechanisms to explain several cellular changes in hyper-
glycemia. With new knowledge of this pathway and availabil-
ity of novel aldose reduction inhibitors we will probably see
new clinical trials in the near future.
Inﬂammation or other changes like augmented polyol
pathway activity leads to oxidative stress in the retina which
disrupts the ﬁne balance between formation and elimination
o fr e a c t i v eo x y g e ns p e c i e s .D r s .K o w l u r ua n dC h a nh a v ee m -
phasized that several metabolic abnormalities which are im-
plicated in diabetic retinopathy are inﬂuenced by oxidative
stress. Although currently little clinical data is available as
to the eﬀectiveness of blocking such pathways for the treat-
ment of diabetic retinopathy, antioxidant treatment remains
an attractive future option for pharmacotherapy for diabetic
retinopathy. In an accompanied research article this group
has also demonstrated that peroxinitrite accumulation and
impaired scavenging of mitochondrial superoxide may be an
important mechanism in the pathogenesis of retinopathy.
In a research article, Dr. Canning et al. demonstrated the
role of advanced glycation end products (AGEs) and galectin
3 with AGE binding properties in the blood retinal bar-
rier breakdown and VEGF upregulation. This research reem-
phases the importance of such mechanisms in the pathogen-
esis of early changes in diabetic retinopathy.
Furthermore, Drs. Khan and Chakrabarti discussed a
plethora of intracellular signaling mechanisms ranging from
second messengers, transcription factors to transcription
coactivators that are of importance in functional and struc-
turalchangesinthemicrovasculatureindiabeticretinopathy.
Dr. Pulido et al. addressed the relationship between dia-
betic retinopathy and elevated glutamate level. Such elevated
glutamate levels may have toxic eﬀects. In an accompanied
research article this group also demonstrated a method for
detection of glutamate.
Dr. Ross et al. reported results of an interesting clinical
study from Alberta, Canada. They have demonstrated that
ethnicity does play a role in the development of diabetic
retinopathyalthoughtheriskfactorsaresimilarbetweenvar-
ious populations.
Finally, Drs. Schwartz and Flynn discussed clinical ex-
perience with various pharmacological treatments. As more
dataisavailable,theroleofsuchtreatmentwillbeclearerand
mayprovidenewadjuvanttreatmentinadditiontophotoco-
agulation and laser treatment of diabetic retinopathy.2 Experimental Diabetes Research
These articles, hopefully, will provide better understand-
ing of this process and bring forward new ideas with respect
to the development of newer adjuvant treatment modalities.
However, as evident from these articles as well as data in the
literature, the pathogenetic mechanisms involved in diabetic
retinopathy are interactive and interdependent. Hence, eﬀec-
tive future treatment strategies may include multiple phar-
macological agents, targeted simultaneously to block multi-
ple pathways.
Obviously not all aspects of this ﬁeld could be addressed
in one issue and I extend my apologies to many contribu-
tors of this ﬁeld whose work has not been covered. I thank all
the authors who contributed to this issue and the reviewers
for the highly constructive and helpful comments. My sin-
cere thanks to Dr. A. A. F. Sima for providing me with an
opportunity to work as an editor of this issue. It has been my
distinct privilege to work with these excellent scientists.
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